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Background: The use of molecular techniques is a major improvement for the rapid routine
detection and control of multidrug-resistant tuberculosis (MDR-TB).
Materials: In this study, the multiplex allele-specific polymerase chain reaction (MAS-PCR)
was developed to simultaneously detect the most frequent mutations associated with iso-
niazid (INH) and rifampin (RIF) resistance in a single assay.
Results: The assay was tested with 53 clinical isolates. Among them, 27 were MDR strains,
17 were mono-resistant to INH, one was mono-resistant to RIF, and eight were susceptible.
The MAS-PCR assay showed a specificity of 100% in detecting drug resistance. An equiva-
lent sensitivity of 92.6% in detecting MDR and RIF-resistance was found. The sensitivity
for the detection of INH-resistance was 88.6%.
Conclusions: The MAS-PCR assay was a simple and rapid method for detecting the INH and
RIF-resistance in Mycobacterium tuberculosis (MT) clinical strains. It is also easy to perform
and to interpret. The assay is inexpensive and a less-demanding technique.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction more complex genetic system that involves several genes,Unfortunately, Mycobacterium tuberculosis (MT) is still regarded
as a causative agent with high morbidity and mortality
throughout the world [1,2]. The emergence of multidrug-
resistant tuberculosis strains (MDR) has complicated the suc-
cess of treatment and leads to the failure of its eradication. By
definition, the MDR strains are resistant to at least rifampin
(RIF) and isoniazid (INH). The rapid detection of such strains
is essential for the efficient control of the development of
MDR strains [3]. Several studies have demonstrated that RIF-
resistance of MT is largely associated with mutations in a
hot spot 81 pb rpoB region. INH-resistance is controlled by a-African Society for Myco
ratory, Abderrahmen Ma
-Saidi).such as katG, inhA, ahpC [4,5], and ndh [6–17]. Many conven-
tional approaches allow for detection of these resistance
strains, however, they are usually time-consuming. There-
fore, tuberculosis (TB) laboratories adapted new methods,
including DNA sequencing [18], line probe assay [19], single-
strand conformation polymorphism [20,21] allele = specific
PCR assay [3,22,23], real time PCR, molecular beacons
[24,25], DGGE [26], PCR RFLP [4], single-tube heminested PCR
[27], INNO-LiPA [28], and MTBDRplus [29].
The aim of this study was to develop a method for rapid
identification of drug resistance and simultaneous detection
of INH- and RIF-resistance associated genetic mutation.bacteriology. All rights reserved.
mi Hospital of Pneumology, Ariana 2080, Tunisia. Tel.: +216 7 182
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was used that simultaneously detects INH- and RIF-resistance
associated genetic mutations.
Materials and methods
Bacterial strains and drug susceptibility testing
Fifty-three strains of MTB were isolated from unrelated TB
patients in the microbiology laboratory of Abderrahmen
Mami Hospital of Pulmonology in Tunisia during the period
2002–2005. Species identification of the isolates was based
on standard microbiological tests, including colony morphol-
ogy in Lo¨wenstein–Jensen (L–J) medium, acid-fast staining,
and biochemical tests [30,31]. The phenotypic proportion
method of Canetti was used for drug susceptibility testing
[32]. An isolate was considered resistant if bacterial growth
occurred at concentrations of 0.2 micrograms (lg) of INH/mil-
liliter (ml) and 40 lg of RIF.
DNA extraction
Genomic DNAwas extracted from cultures grown in L–J med-
ium using the QIAGEN QIAamp DNA mini kit tissue protocol.
Briefly, a loop of organisms was suspended in 180 microliter
(ll) of lysis buffer, add 20 ll of proteinase-K, incubate at
56 C for 2 h, and continue with steps of centrifugation. DNA
was purified through a spin column as recommended by the
manufacturer. After elution, the obtained DNA was directly
used for amplification or conserved at 20 C.
MAS-PCR
A multiplex allele-specific PCR was used to target codon 516,
526, and 531 of the rpoB gene, the codon 315 of the katG gene
and the mabA-inhA promoter region (15). These codons
were most frequently involved in point mutations associated
with RIF- and INH-resistance in different previous studies
[6–8,14].
Design of primers of MAS-PCR to detect INH- and RIF-resistance
mutations of MT
The MAS-PCR assay used five allele-specific primers corre-
sponding to the five codons targeted and three primers paired
with 1–3 of the five allele-specific primers (Table 1). The 3 0 end
of each allele-specific primer is paired with the wild typeTable 1 – Primers of MAS-PCR used to detect INH- and RIF-resis
Target genes Allele-specific primers (50–3 0) and pai
katG 315 katG5R (+) ATACGAC
katGOF () GCAGATG
mabA-inhA: 15 InhAP 15 (+) GCGCGGT
InhAPF2 () CACCCCG
rpoB 516 rpoB 516 (+) CAGCTGA
RIRm () TTGACCC
rpoB 526 rpoB 526 (+) CTGTCGG
RIRm () TTGACCCsequence in the respective codons. Consequently, in the ab-
sence of mutation at target codon, thewild type allele-specific
fragment will be amplified, and if the mutation occurred, no
allele-specific PCR product will be obtained [3]. For each
MAS-PCR reaction, a 50 ll reaction mix was used; it consisted
of eight primers: 2 ll rpoB 516 (1 lM), 2 ll rpoB 526 (1 lM), 3 ll
rpoB 531 (1 lM), 5 ll RIRm (1 lM), 1 ll katGOF (1 lM), 1 ll katG5R
(1 lM), 1 ll inhAP-15 (1 lM) and 1 ll inhAPF (1 lM). 10 ll of 5·
reaction buffer, 4 ll MgCl2 (2 mM), 1 ll of each dNTP (200 lM),
0.25 ll GoTaq (Promega) 1.25 U/I, 4 ll DNA solution (50–
400 ng), and 9.75 ll sterile water. Amplification was carried
out in a GeneAmpR PCR system 9700 (Applied Biosystems)
according to the following program:
An initial denaturing for 3 mn, 23 cycles of 95 C for 50 s;
68 C for 40 s; and 72 C for 1 mn, and a final extension at
72 C for 7 mn.
The PCR products were analyzed by 5% polyacrylamide gel
electrophoresis for 2 h 30 mn.
Results
Drug susceptibility
Out of 53 strains, 27 isolates were MDR (50.94%) and eight
were susceptible (15.09%). The remaining isolates weremono-
drug-resistant (17 resistant to INH, one resistant to RIF).
Results of MAS-PCR
The MAS-PCR products were visualized by polyacrylamide gel
electrophoresis and generated different banding pattern
corresponding to different mutation profiles (Fig. 1).
The presence of five bands corresponding to sizes: 292-
bp, 270-bp, 218-bp, 185-bp, and 170-bp represent the specific
banding patterns for the susceptible strains. The RIF
resistance is defined by the absence of one or more of three
correspondent bands: 218-bp, 185-bp, and 170-bp. The INH
resistance is indicated by the absence of the 292-bp band
when mutation in katG codon 315 alone, and by the absence
of 270-bp band when mutation relates to 15 position of the
mabA-inhA promoter region. Drug susceptibility testing de-
tected 28 strains resistant to RIF. The mutation at codon
531 of the rpoB gene was the most frequent (67.8%). This
mutation was found as the only genetic support in 19
isolates (67.8%). It was combined to a mutation at codon
526 in four isolates (14.3%). One isolate harbored a tripletance mutations of M. tuberculosis.
red primers Length of PCR products (bp)
CTCGATGCCGC 292
GGGCTGATCTACG
CAGTTCCACA 270
ACAACCTATCG
GCCAATTCATGGA 218
GCGCGTACAC
GGTTGACCCA 185
GCGCGTACAC
Fig. 1 – Results of MAS-PCR shown by 5% polyacrylamide gel electrophoresis. The 292-bp band represents the katG codon 315
specific PCR product; the 270 bp band represents the 15 promoter region ofmabA-inhA specific PCR product; the 218-bp band
represents the rpoB codon 516 specific PCR product; the 185-bp band represents the rpoB codon 526 specific PCR product; and
the 170-bp band represents the rpoB codon 531 specific PCR product. The smallest band shown on the gel associated with the
amplification of 218-bp fragment is a non-specific band. The first lane on each panel represents the 100-bp DNA ladder
(Promega). Lanes 3 and 9 represent two clinical isolates that had no mutation at any of the codons investigated. The
remaining lanes on both panels represent isolates which had point mutation(s) at the targeted loci. Lanes 1, 2, 4, 5, 6, 7, 8,
katG codon 315 and rpoB 531; lanes 11 and 12 katG codon 315 and mabA-inhA (15); lanes 13 and 15, mabA-inhA (15); lanes
10 and 14, katG codon 315, mabA-inhA and rpoB codon 531; lane 16, katG codon 315.
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mutations at codons 516 and 526 were found in one strain
for each. Of the 44 INH-resistant isolates, the MAS-PCR re-
vealed an unique mutation at codon 315 of the katG gene
in 28 strains (63.6%) and 4 (9.1%) isolates carried a combined
mutation with codon 15 of the inhA regulatory region. The
mutation in the inhA regulatory region was detected alone in
seven strains. No mutations were detected in 11.4% and
7.19% for respectively INH and RIF resistant strains (Table
2). In comparison to the conventional proportional method,the MAS-PCR results were able to detect 48 of 53 strains
studied. The agreement with drug susceptibility testing
was 90.5%.
Sensitivity and specificity
Using the conventional drug susceptibility testing as the ‘‘gold
standard,’’ the sensitivity and the specificity of the MAS-PCR
for detecting MDR, INH and RIF resistance were assessed
(Table 3).
Table 3 – Sensitivity and specificity of MAS-PCR assay for detecting M. tuberculosis resistance to INH and RIF.
MAS-PCR results Culture results Sensitivity (%) Specificity (%)
Susceptible Resistant
INH mutations
Detected 0 39 88.6 100
Not detected 9 5
RIF mutations
Detected 0 26 92.8 100
Not detected 25 2
MDR mutations
Detected 0 25 92.6 100
Not detected 26 2
Table 2 – Mutations detected by MAS-PCR associated with INH- and RIF-resistance and their frequency.
Genes Rifampicin Isoniazid
rpoB katG inhA katG + inhA
Mutations 516 526 531 526 + 531 516 + 526 + 531 315 15C 315+ (15C)
Number of strains 1 1 19 4 1 28 7 4
Frequency (%) 3.57 3.57 67.8 14.3 3.57 63.6 15.9 9.1
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remaining 26 non-MDR strains were also identified as non-
MDR by MAS-PCR. The sensitivity of MAS-PCR assay for
MDR detection was 92.6% and the specificity was 100%. The
MAS-PCR detected 26 of the 28 RIF-resistant isolates. The
sensitivity was 92.8% for detecting RIF-resistance. All the 25
RIF-susceptible strains showed a susceptible pattern using
the molecular method producing a specificity of 100%. Con-
cerning INH resistance, 39 of the 44 INH-resistant isolates
were identified using the MAS-PCR method. The molecular
method showed a sensitivity of 88.6% for detecting INH-resis-
tance. The specificity was 100% as the nine susceptible iso-
lates harbored a wild type allele-specific pattern.
Discussion
In order to support an early diagnosis of the disease and to
control the diffusion of MDR strains, many molecular meth-
ods have been developed showing high specificity and signif-
icant sensitivity in resistance detection.
Based on published studies [3,22,23], a MAS-PCR assay was
chosen which allows for the simultaneous detection of INH
and RIF resistance and evaluated drug resistance
mechanisms.
More than 90% of the MDR-TB cases were detected by
MAS-PCR in this study. This molecular method could predict
with a sensitivity of 92.6% and specificity of 100% the MDR
strains. This approach reduced the identification time of
MDR-TB from several weeks to 5 days. The application of such
a technique is very wide in the prevention and control
measurements.
Among the 28 RIF-resistant strains tested, 26 showed a
mutation at 516, and/or 526 and/or 531 codon. Thesemutations represent the most frequently mutated codons
worldwide [6,7].
The most prevalent mutation affected codon 531 (85.67%),
followed by codon 526 (21.44%) and codon 516 (7.14%). Muta-
tions at codon 531 occurred alone in 67.8% of cases. Multiple
mutations were also found with a double mutation associat-
ing codons 513 and 526 (14.3%) and a triple mutation carried
out by one strain (3.57%). Unique mutation at codons 526
and 516 were found in one strain for each (3.57%). Several
studies also showed that a mutation at codon 531 predomi-
nated worldwide like in Poland [33], Turkey [8] and in India
[9]. Therefore, detecting these mutations is well related to
identifying RIF-resistance strains.
The molecular method was not able to identify RIF resis-
tance in two strains (7.1%). Other mutations in the 81-bp
hot spot region could be involved. Studies undertaken in Italy,
Africa and Australia found mutations at codons 504 [12], 541,
553 [11] and 572 [13]. Mutations outside the 81-bp rpoB core re-
gion are rarely described and are revealed using sequencing
in less than 5% of RIF-resistant strains [9,34]. The sensitivity
of MAS-PCR in RIF-resistance detection was 92.8% and the
specificity was 100%. This high rate is related to the simulta-
neous detection of the most frequently mutated codons in-
volved in RIF-resistance.
Concerning INH resistance, 39 of 44 INH-resistant strains
were detected by the MAS-PCR assay. Results showed a high
frequency of the katG 315 codon mutation (72.7%), whereas
the -15 inhA mutation is less frequent (25%). These mutations
occurred alone in 63.6% and 15.9% of cases for respectively
katG 315 and 15inhA, and were combined in 9.1% of cases.
Several studies described the prevalence of the katG 315muta-
tion which frequency is about 70% to 85% [7,35,36]. In North-
western Russia, it is highly prevalent and was found in 93.6%
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mutations in the promoter region of the inhA gene occurred
in 20–34% of strains, which is in agreement with our results
[36,29]. The addition of this mutation led to an improvement
in the rate of detection of INH-resistance of 91%. Discrepan-
cies between phenotypical and the molecular methods were
observed for five resistant strains that harbored no mutation
using theMAS-PCRmethod. In fact, INH-resistance is complex
and many genes may be involved, including kasA [16], ndh,
hpC [17] and the oxyR-ahpC intergenic region [4–7,36]. Conse-
quently, MAS-PCR assay showed a sensitivity of 88.6% and a
specificity of 100% for detecting INH-resistance.
Conclusions
To conclude, the MAS-PCR assay was a simple and rapid
molecular method for identifying the INH and RIF resistance
in MT clinical strains. It is also easy to perform and to inter-
pret. The assay is inexpensive and requires only electrophore-
sis equipment and can be used in the routine practices of
clinical laboratories in regions with a high prevalence of
MDR-TB strains [3,22].
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